Anti-SARS-CoV-2 Spike NTD (Clone 2146) – HRP

Anti-SARS-CoV-2 Spike NTD (Clone 2146) – HRP

Product No.: LT2010

- -
- -
Product No.LT2010
Clone
2146
Target
SARS-CoV-2 Spike NTD
Product Type
Recombinant Monoclonal Antibody
Alternate Names
COV2-2146, SARS-CoV2 Spike NTD, COVID-19, 2019-nCoV, Severe acute respiratory syndrome coronavirus 2, SARS-CoV2
Isotype
Human IgG1
Applications
ELISA
,
IHC

- -
- -
Select Product Size

Data

Anti-SARS CoV-2 NTD, Clone 2146 ELISA DataCoating: Purified Recombinant SARS-CoV-2 Spike NTD (Prod. No. S853) concentration of 1 ug/ml, 100 ul/well overnight at 2-8°C. Detection: Anti-SARS-CoV-2 NTD (Clone 2146) conjugated to HRP was serially diluted starting at 25 ng/ml down to 0.23 ng/ml, 100 ul/well for 1 hour at 37°C. Substrate: TMB (Leinco T118), 100 ul/well for 15 min. at room temperature followed by Leinco 450 nm Stop Solution (Leinco T125), 50 ul/well.
- -
- -

Antibody Details

Product Details

Reactive Species
SARS-CoV-2
Virus
Expression Host
HEK-293 Cells
Immunogen
Sequenced from human survivors of COVID-19 (SARS-CoV-2)
Product Concentration
0.5 mg/ml
Formulation
This recombinant HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. <b> (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)</b>
Storage and Handling
This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Overnight on Blue Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
Additional Applications Reported In Literature ?
IHC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-SARS-CoV-2 Spike NTD-HRP, clone 2146, specifically targets an epitope on the SARS-CoV-2 spike protein N-terminal domain.
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells3-5. The NTD of SARS-CoV-2 does not bind to ACE26, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties7 and might play a role in the conformational change of S2 required for membrane fusion8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV10.
Antigen Distribution
The spike NTD is expressed on the surface of SARS-CoV-2.

Antigen Details

NCBI Gene Bank ID
Research Area
COVID-19
.
Seasonal and Respiratory Infections
.
Viral
.
IVD Raw Material

References & Citations

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Wrapp D, Wang N, Corbett KS, et al. bioRxiv. 2020.
4. Walls AC, Park YJ, Tortorici MA, et al. Cell. 181(2):281-292.e6. 2020.
5. Li W, Zhang C, Sui J, et al. EMBO J. 24(8):1634-1643. 2020.
6. Wang Q, Zhang Y, Wu L, et al. Cell. 181(4):894-904.e9. 2020.
7. Park, Y., Walls, A.C., Wang, Z. et al. Nat Struct Mol Biol 26, 1151–1157. 2019.
8. Zhou, H., Chen, Y., Zhang, S. et al. Nat Commun 10, 3068. 2019.
9. Chi X, Yan R, Zhang J, et al. Science. eabc6952. 2020.
10. Ou, X., Liu, Y., Lei, X. et al. Nat Commun 11, 1620. 2020.
Indirect Elisa Protocol
IHC

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.